The partners will use Akoya's multiplex immunofluorescence platform for spatial phenotyping and JHU's AstroPath platform to identify predictive signatures.
The partners will use mass spec to look at markers in Barrett's patients who either progressed to more severe disease states or remained stable over a 10-year period.
The startup biotech has spent four years researching PRDM genes in various cancers and is coming out of stealth mode with a lead candidate in lung cancer.
This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.
This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.
